research use only

Carmustine DNA/RNA Synthesis inhibitor

Name: Carmustine
Brand: Selleck Chemicals
SKU: S3669
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S3669

Carmustine (bis-chloroethylnitrosourea, BCNU, BiCNU) is a cell-cycle phase nonspecific alkylating antineoplastic agent and used in the treatment of brain tumors and various other malignant neoplasms.

Carmustine DNA/RNA Synthesis inhibitor Chemical Structure

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	HDAC PARP ATM/ATR DNA-PK WRN Topoisomerase PPAR Sirtuin Casein Kinase eIF
Other DNA/RNA Synthesis Inhibitors	CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 EED226 BMH-21 Carmofur Triapine (3-AP) YK-4-279 Halofuginone

Solubility

In vitro
Batch:

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.000mg/ml (9.34mM)	Taking the 1 mL working solution as an example, add 50 μL of 40 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	214.05	Formula	C₅H₉Cl₂N₃O₂	Storage (From the date of receipt)	3 years, -20°C
CAS No.	154-93-8	Download SDF		Storage of Stock Solutions	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.
Synonyms	bis-chloroethylnitrosourea, BCNU, BiCNU			SMILES	C(CCl)NC(=O)N(CCCl)N=O

Read more about storage stability CAS number SMILES

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-10)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05521984	RECRUITING	Pediatric Brain Tumor; Pediatric Solid Tumor	Washington University School of Medicine	2023-04-03	PHASE1
NCT04871607	RECRUITING	Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma	City of Hope Medical Center	2021-11-02	PHASE2
NCT04222062	RECRUITING	Brain Tumor - Metastatic	University of Nebraska	2020-11-06	PHASE2
NCT07774299	NOT_YET_RECRUITING	DLBCL	Ruijin Hospital	2026-08-25	PHASE2
NCT06687772	RECRUITING	Diffuse Large B Cell Lymphoma	Washington University School of Medicine	2025-01-16	PHASE2
NCT07199296	RECRUITING	Mantle Cell Lymphoma (MCL)	Ruijin Hospital	2025-07-01	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):